Consumer: Page 7

Can cheap test prevent newborn deaths? | Amino acid desmosine as biomarker in aneurysms | Brouhaha over DTC genetic tests
By Emily Hayes
Dear LabPulse Member,
October 21, 2019
Demand for early detection drives global IVD market growth
By Bruce Carlson
Hundreds of companies are involved in the IVD market, and there are many new entrants, along with pharmaceutical, financial, and technology companies that are playing a role, according to the annual report, which profiles more than 200 companies. Kalorama predicted the market will grow a little more than 4% annually to reach $85.2 billion by 2024, including all sales of instruments, reagents, test kits, and supplies and directly related software and services.
September 26, 2019
2019 04 26 21 48 5250 Money Hundred Bills 400
Fisher set to market Verax platelet contamination test
By LabPulse.com staff writers
The test is used to detect bacterial contamination in apheresis platelets in plasma to ensure the safety of blood transfusions. It can be used to extend platelet dating, which potentially saves money by allowing the extended use of products that may otherwise need to be thrown away, according to the company. The product had been distributed by Fenwal/Fresenius Kabi, which is focused on distribution in blood centers, whereas Fisher Healthcare has a large presence in thousands of hospitals, an important target market for Verax, the company explained in a statement.
August 19, 2019
2019 04 24 17 43 1766 Hands Shaking2 400
Abbott unwraps diagnostics technology platform
By LabPulse.com staff writers
Offered as part of Abbott's AlinIQ professional services and informatics portfolio, the Integrated Platform's initial service -- Business Performance -- will target operational efficiencies in the lab. Leveraging Abbott's operational analysts and the platform's ability to gather data from multiple sources, the Business Performance package can identify insights that could result in lower lab administrative and processing costs and enable technicians to focus on analyzing diagnostic results, Abbott said. The Business Performance package is available now in the U.S.
August 6, 2019
2019 08 07 17 18 6681 Data Analytics 400
Direct-to-consumer tests in AACC spotlight | Blood tests for Alzheimer's disease | Transgender reference values wanted
By Emily Hayes
Dear LabPulse Member,
August 5, 2019
AACC: Labs should be aware of false positives on THC drug screens
By Emily Hayes
Cannabinol (CBN), which is marketed as an over-the-counter sleep aid, gave a positive result on one of two THC immunoassays tested in a study of urine samples taken at ARUP Laboratories, a nationwide clinical and anatomical pathology reference laboratory and a nonprofit arm of the University of Utah. Specifically, CBN gave a positive result on the Emit II Plus assay on a Beckman Coulter AU5810 instrument, but it did not give a positive result with the Microgenics MultiGent test on the Abbott Architect product, the researchers reported.
August 5, 2019
2019 08 05 17 59 6641 Aacc 2019 400
GNA Biosolutions secures $13.5M in new funding round
By LabPulse.com staff writers
GNA said it plans to use the funds to advance the development of its point-of-care molecular diagnostic platform as well as help bring it to the clinic -- first in the European Union and then in the U.S. market. The platform can support the creation of simple, cost-effective molecular diagnostic tests and has already facilitated the production of more than 30 internal assays for hospital-acquired infections and tuberculosis, among other diseases, according to the firm.
August 4, 2019
2019 08 05 19 10 8249 Dollar Sign 400
AACC: Labs grapple with 'double-edged sword' of direct-to-consumer testing
By Emily Hayes
The AACC meeting, being held August 4-8, featured the panel on consumer genomics, direct-to-consumer testing, and patient empowerment as a special session moderated by Minnesota Public Radio journalist Cathy Wurzer on the opening day.
August 4, 2019
2019 08 05 17 59 6641 Aacc 2019 400
LabCorp builds on consumer tests
By LabPulse.com staff writers
The move represents an expansion of the company's Pixel by LabCorp direct-to-consumer platform, which now includes almost 90 lab tests, such as ones for cardiovascular health, diabetes and kidney function, and general wellness. Tests are also bundled into packages; for example, LabCorp has a women's health bundle. Consumers pay for testing through the company's Pixel website and then visit one of LabCorp's nearly 2,000 patient service centers in the U.S., which include locations at Walgreens pharmacies.
July 22, 2019
2019 06 21 23 50 8190 Blocks Growth Increase 400
GlaxoSmithKline recruits SpeeDx for antibiotics trials
By LabPulse.com staff writers
SpeeDx markets in vitro testing products internationally that are aimed at minimizing the spread of treatment-resistant infections. Such products include ResistancePlus GC for Neisseria gonorrhoeae bacteria, which recently received the breakthrough device designation from the U.S. Food and Drug Administration (FDA), and ResistancePlus MG for detecting the emerging sexually transmitted infection Mycoplasma genitalium (Mgen). In a statement, the company said that it will use its existing molecular diagnostic tests as well as custom products to assist GlaxoSmithKline in ongoing trials and new product development.
June 23, 2019
2019 05 24 21 56 3410 Gonorrhea Neisseria Gonorrhoeae 400
Biocept launches 12-gene breast cancer liquid biopsy test
By LabPulse.com staff writers
The breast cancer panel, which is designed for use with Thermo Fisher Scientific's Ion Torrent NGS platform, has sensitivity of more than 90%, specificity of more than 99%, and accuracy of 99.8%, according to Biocept. It is the second Target Selector product to be introduced, after a panel for lung cancer. The company also offers single-biomarker testing on its ctDNA and CTC platforms.
June 17, 2019
2019 05 15 22 45 9236 Lab Blood Dna 400
GenomeSmart launches genetic testing platform
By LabPulse.com staff writers
Developed with input by genetic counselors, the product -- GenomeBrain -- takes into account an individual's age, medical history, and ethnicity in making recommendations. The platform runs through millions of combinations and produces a personalized report for an individual patient in 10 minutes, which can help testing labs speed up their pretesting workflow and ensure eligibility for insurance reimbursement. Recommendations for genetic testing from guidelines are regularly updated.
May 20, 2019
2019 05 21 17 18 9591 Scientist Woman Dna 400
Previous Page
Page 7 of 8
Next Page